SEC Comment Letter for Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — Jun 6, 2017

Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: June 6, 2017 · CIK: 0001534120 · Accession: 0000000000-17-019665

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

June 6, 2017

Author

Uli Hacksell

Form

UPLOAD

Company

Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)

Letter

June 6, 2017 Uli Hacksell President and Chief Executive Officer Cerecor Inc. 400 E. Pratt Street, Suite 606 Baltimore, Maryland 21202 Cerecor Inc. Registration Statement on Form S-3 Filed May 26, 2017 File No. 333-218252Re: Dear Dr. Hacksell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at (202) 551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

June 6, 2017
Uli Hacksell
President and Chief Executive Officer
Cerecor Inc.
400 E. Pratt Street, Suite 606
Baltimore, Maryland 21202
Cerecor Inc.
Registration Statement on Form S-3
Filed May 26, 2017
File No. 333-218252Re:
Dear Dr. Hacksell:
        This is to advise you that we have not reviewed and will not review your registration
statement.
        Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
        Please contact Jeffrey Gabor at (202) 551-2544 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io